Center for Systems Biology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02124, USA.
JACC Cardiovasc Imaging. 2009 Oct;2(10):1213-22. doi: 10.1016/j.jcmg.2009.04.016.
The aim of this study was to iteratively develop and validate an (18)F-labeled small vascular cell adhesion molecule (VCAM)-1 affinity ligand and demonstrate the feasibility of imaging VCAM-1 expression by positron emission tomography-computed tomography (PET-CT) in murine atherosclerotic arteries.
Hybrid PET-CT imaging allows simultaneous assessment of atherosclerotic lesion morphology (CT) and may facilitate early risk assessment in individual patients. The early induction, confinement of expression to atherosclerotic lesions, and accessible position in proximity to the blood pool render the adhesion molecule VCAM-1 an attractive imaging biomarker for inflamed atheroma prone to complication.
A cyclic, a linear, and an oligomer affinity peptide, internalized into endothelial cells by VCAM-1-mediated binding, were initially derivatized with DOTA to determine their binding profiles and pharmacokinetics. The lead compound was then (18)F-labeled and tested in atherosclerotic apoE(-/-) mice receiving a high-cholesterol diet as well as wild type murine models of myocardial infarction and heart transplant rejection.
The tetrameric peptide had the highest affinity and specificity for VCAM-1 (97% inhibition with soluble VCAM-1 in vitro). In vivo PET-CT imaging using (18)F-4V showed 0.31 +/- 0.02 SUV in murine atheroma (ex vivo %IDGT 5.9 +/- 1.5). (18)F-4V uptake colocalized with atherosclerotic plaques on Oil Red O staining and correlated to mRNA levels of VCAM-1 measured by quantitative reverse transcription polymerase chain reaction (R = 0.79, p = 0.03). Atherosclerotic mice receiving an atorvastatin-enriched diet had significantly lower lesional uptake (p < 0.05). Furthermore, (18)F-4V imaging in myocardial ischemia after coronary ligation and in transplanted cardiac allografts undergoing rejection showed high in vivo PET signal in inflamed myocardium and good correlation with ex vivo measurement of VCAM-1 mRNA by quantitative polymerase chain reaction.
(18)F-4V allows noninvasive PET-CT imaging of VCAM-1 in inflammatory atherosclerosis, has the dynamic range to quantify treatment effects, and correlates with inflammatory gene expression.
本研究旨在逐步开发和验证一种(18)F 标记的小分子血管细胞黏附分子(VCAM-1)亲和配体,并通过正电子发射断层扫描-计算机断层扫描(PET-CT)证明在小鼠动脉粥样硬化血管中成像 VCAM-1 表达的可行性。
混合 PET-CT 成像可同时评估动脉粥样硬化病变形态(CT),并可能有助于个体患者的早期风险评估。黏附分子 VCAM-1 的早期诱导、局限于动脉粥样硬化病变的表达以及靠近血池的可接近位置,使其成为易发生并发症的炎症动脉粥样硬化的有吸引力的成像生物标志物。
最初用 DOTA 衍生出通过 VCAM-1 介导的结合进入内皮细胞的环状、线性和低聚亲和肽,以确定它们的结合谱和药代动力学。然后将先导化合物(18)F 标记并在接受高胆固醇饮食的动脉粥样硬化 apoE(-/-)小鼠以及心肌梗死和心脏移植排斥的野生型小鼠模型中进行测试。
四聚体肽对 VCAM-1 具有最高的亲和力和特异性(体外 97%抑制可溶性 VCAM-1)。使用(18)F-4V 的体内 PET-CT 成像显示在小鼠动脉粥样硬化中为 0.31 +/- 0.02 SUV(离体 %IDGT 为 5.9 +/- 1.5)。(18)F-4V 摄取与油红 O 染色的动脉粥样硬化斑块共定位,并与定量逆转录聚合酶链反应测量的 VCAM-1 mRNA 水平相关(R = 0.79,p = 0.03)。接受富含阿托伐他汀饮食的动脉粥样硬化小鼠的病变摄取显著降低(p < 0.05)。此外,在冠状动脉结扎后的心肌缺血和排斥的移植心脏同种异体移植物中,(18)F-4V 成像显示在炎症性心肌中有高的体内 PET 信号,并与定量聚合酶链反应测量的 VCAM-1 mRNA 的体外测量具有良好的相关性。
(18)F-4V 可实现炎症性动脉粥样硬化中 VCAM-1 的非侵入性 PET-CT 成像,具有定量治疗效果的动态范围,并与炎症基因表达相关。